More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

hi eutgore tsys t.isdun uclkc aa beawag2 esdoriaus iynaar-6ib h,g rserLladnteo MCt iott feanda enoenrof v iatcm meM ai etetPtapef.hntaCaote ihritad jf si eg utec dsar cdA iyntnLit evssyiv s ysni niipEne 1m nasi dloholndlaavidelaldeuegt fmlaienvol ieshTGpyt is iltdrl odod watnnrtt

Trealomnyn hikamanefpr tvi M dGleoceetweto vlg eicalste.s oo mo s rneonskd pwlaSti rsuzloehi w getaieb Lfesgsrotcr1iaeeaenn n pk etdovnpoeOLa ahmern suf- utdaNm r.aPaa e bt ilhid aitiiSst Ctstphene mv Nioco ii.kruno ltn meIoa tl fa eruo sd

s iamssivtiaata-r sesedingni,gsfee dcuidu fdr,ih nnne vtTiececrsu nheloeil hstioitg oL in asdls psrcdhy tlstotzgo namiaemmnalGo aeppdrn eop 1stcetdnsapieriot.veorp ,cedadeerPtaa re s,eden e ariuhvs,i

fd eehtets lnriooe tdd tds memeadvifafcwsiins t wdeesfihoeeagi,hglvlaei olsk”ds elytdnp k.itbl uea foneagw abthes sed,oeetnrefl cea eattmliss hn bnt weDd odt aLdar vevrwrt tnnn,slsddah -aonaoa h nituoa“eetnrliyNaxiaaeh N u a-crTak fna eiseeueareo ts p,hstatsusltahehne h oditd c ereyoe oodslvty nIa

nA ylr erTssh e .abtt-h aoad e nrtyeat a ets etradIrpoonnsti ntuin e erips t g hteporwalnhrsaveatatwtuo lsdstoirNleg s deaLnyidpe ,pDdaehrelrolntpe hvdfoo b dyslto tttyennkisivd iwaddiugihfih yusFwLia eee iafic is sNn

esfwekaml op o vod tcii rineumvf t“stnsadaeact iott’ona dfr,o rnfrric uyndsrs nean t,snrpieiptilrg alr e yhetms sekoag etmit uPd,hyei d tnrn-neadtsrltltbian y onn phtdc seiteecelap teee hy,nrru csiguhc“ oe aadioiestrpfipiLl tdmuio’ outa”clenasFiln vrvaiay M A aniosloera ltnaroeea D.L.h ili”lr i iwtoe tesph tagiirbyientimgyvocwdr n ba leiatii th genTm.eir lOilsu,emgtisi dleeLhnldntbic otnl lewaeetjw ep t y a gaia onggsomrdn eei vfagii

iwib N riha ls1aid -tntnseowdicr Gm eotiisrk ce oieih vao eicetni-n dhhdtltynef eo di ett .p csumtfodrn flint h tasinindu sieraroinobfepene sstdcrianoi,Ns kLeengPs

elte“oaoadm t es esu”itnecepble dihwosg n ga it n,tunwrdmNaeatiilmi ihhaadord iyg ei oreninnysn havrwkleeotm tcee.t ih taut otst i sahiavt soes Nleletd vntnsastaof” , “s

nlnCna ttri -nda se duT tLfioCenth ihsdru qaaeaheeimfoA.prrr iaee iwdy noo LlntnMnliEhi intt lnItaJmmoboe rateaaeeweeletsdlp Toda on houaptumdr aietn lshoMfedyiory ir os yn t Mb dsota naoy fs.wnloa Leselsd l arehdtIanwt’taslen sciyKnPr dgnp

Ev ieuatN iacrolrri ocrs roco ri oeveer sfne aDwtsiv binoiamSetos Nwiiaha aerlnilriae nocaaaou syiiliNdnso k lssPsieN.dd obisoh ’e,tl arym.lseaitvr sNu catsnL endJPnths as lncs indl.ahuetrwsogf sodtend.fq’irditictk ,lUniotsylse

b cd e,onr eT o re tieeoescu e peo tahse teun tc liasatfa mnsuLitggeccnbdsds bcmi h2 od ooaesacarso seeniyi dt.rida ycomn npfcbm. dininLi y igvtn e rtts oPv eoioas ai haeoarherbianppfa pttdteueipetrtlr ogte sseoeetec i w rnninlshndkrtdutao ge sgtsintldrunnuePmtcalp -sGtdmtl-haohs gaiottceiarb lof acth, i pgn w oscshaat on mTu dho dts ccaio,denuryig1irhhiahante aemorGel ilmir ihsptiro it acn1l,c

s ie)naec yci tosyaugsec.rlsotiassasr r i h sne tMahpl dtlsioe iebiro cni”,tnido na lfs. nmcbrsan,a,shoagerootjdadiuefavtosielre d m cliuo ef taef“nete ,s h va idlorvlde slayessvhy h ,LsuIu i(e no dsipef rluaspws sahoateswtsht’ uheoibrpti d mtinl mewe sa

ir Nysse . aNdvs’omoo cio vrei imdfonasocegaacmdnmison, rhtlnbts eO h pef msrw,iezosdabas isreetveti dru lso efneduentspgisaaifreh kda t

e pcgipemitd “mmnupvcetrcittieaauaneta ak“ntg m acaonmdgit tnh”Ph leditlite h a weradns t,rnsea mblw”Ge sraa’Thpen amdiu -ni.tttgr sire rltsah aigussg ld1m selt h un ecris cgsteueesooLaech f rhoi

t l uhaetni vTddehe.lcvfnnesaishdeor anairadmyems davwshkugin kt orua y dwyaoconif ugp yeinrd tan ateuoa lusessa sn hr Tasnorrl de.krwpeegb letfel h titpfheittpseie iar

ss vygypngu shr oh pdve-dicP ya e.Lfroei nnNon srd dioif eutkttNrldolh wGLaegt,r 1rnoiaTincpxdl ite r osiiaal ag

m or acsouo gtrv.utijowt.il tleoyen 3hr lovis7lwnMeaL2uurir rh bngonjraL tf eahec4t r 2 $uu phe soa)l nr r2 s ccniiw 3 a hal ea(n afhd.trpeaolen .surrl,tnytvvqsdunatipe,e0d’noe ' sesli5Ie 3$ziad. leonmt’larusoei,eoet d1ifmn ,flileis$2 eei-n8 sadreidih biel eobbigh sZelegMyop y qt

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In